The study demonstrated that patients who test positive for ctDNA “actually benefit from chemotherapy.” The CIRCULATE study, a randomized trial involving more than 2,100 patients, has demonstrated that testing for circulating tumor DNA (ctDNA) can improve treatment decisions for colon cancer. Published in Annals of Oncology, the research confirms that ctDNA is a significant risk marker and that patients testing positive for these DNA fragments be…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.